Yüklüyor......
The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas
Prolactinomas are the most frequently observed pituitary adenomas and most of them respond well to conventional treatment with dopamine agonists. However, a subset of prolactinomas fails to respond to such therapies and is considered as dopamine agonist-resistant prolactinomas (DARPs). New therapeut...
Kaydedildi:
| Yayımlandı: | J Endocrinol |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4760866/ https://ncbi.nlm.nih.gov/pubmed/26698564 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/JOE-15-0451 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|